9:41 AM · 28 September 2022

Biogen rallies 50% in premarket on Alzheimer drug trial results

Shares of Biogen, a US biotech company, trade around 50% higher in premarket today. Shares rally following results of an Alzheimer drug (Lecanemab) trial that Biogen developed along with Eisai, Japanese pharmaceutical company. Results showed that the pace of cognitive decline in patients who received Lecanemab dropped by 27% over 18 months compared to patients who received placebo. This is massive as it is the first drug to show effectiveness against Alzheimer in a definitive, large-scale trial. While the company noted that some side effects occurred, it also said that they were rarely severe.

Biogen trades around 50% higher in premarket today. Weekly chart. Source: xStation5

11 June 2026, 8:09 AM

Oracle Beats Q4 Expectations, But Heavy AI Spending Spooks Investors 📉 Stock Down 10% in Premarket

10 June 2026, 3:51 PM

US Open: May Inflation Limits Declines

10 June 2026, 3:43 PM

Food Better than Tech❓Cracker Barrel Surges 32% After Crushing Q3 Earnings 🍳 📈

10 June 2026, 12:15 PM

Photronics after 50% crash📉 Deep value on semiconductors market or a value trap?

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits